Last reviewed · How we verify
Efrane (ENFLURANE)
At a glance
| Generic name | ENFLURANE |
|---|---|
| Sponsor | Baxter |
| Drug class | General Anesthetic |
| Target | Glycine receptor subunit alpha-1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1972 |
Approved indications
- General anesthesia
Common side effects
Drug interactions
- amfepramone
- amfetamine
- benzphetamine
- dexamfetamine
- dexmethylphenidate
- dobutamine
- dopamine
- ephedrine
- epinephrine
- formoterol
- indacaterol
- isometheptene
Key clinical trials
- Local Anaesthetic Day-care Haemorrhoidectomy Challenges Traditional Concepts - a Randomised Controlled Trial (NA)
- Vasodilation Effect of Inhalational Anesthetics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efrane CI brief — competitive landscape report
- Efrane updates RSS · CI watch RSS
- Baxter portfolio CI